Regeneron Pharmaceuticals Inc vs Eli Lilly & Co.
REGN vs LLY — side-by-side comparison from reported financials. REGN leads 2, LLY leads 9 of 11 comparable metrics.
Regeneron Pharmaceuticals Inc
REGN · Healthcare
$745.55+0.81%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | REGN | LLY |
|---|---|---|
| Price | $745.55 | $1 177.20 |
| Market cap | $76.8B | $1.05T |
| Revenue (TTM) | $15.5B | $79.7B |
| Revenue growth | +5.6% | +31.7% |
| Net margin | 27.9% | 33.5% |
| Free cash flow | $3.76B | $18.2B |
| Net cash (debt) | $6.62B | ($35.2B) |
| 1-year price return | +30.8% | +37.6% |
| P/E | 17.8 | 41.6 |
| P/E vs own history (cheap-side %) | 46% | 88% |
| Dividend yield | 0.49% | 0.52% |
| Return on equity | 14% | 93% |
| Altman Z-score | — | 7.10 |
| CV checks passed | 10 of 11 | 11 of 11 |
| Employees | 15,410 | 50,000 |
Full résumé-style profiles: REGN CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.